Compare Ascendis Pharma A/S (ASND) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Novavax Inc — how do they compare? Ascendis Pharma A/S trades at $245.47 (market cap $16.71B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Ascendis Pharma A/S is far larger — about 12.8× Novavax Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| ASND | NVAX | |
|---|---|---|
Market Cap | $16.71B | $1.31B |
Sector | Health | Health |
52-Week High | $277.18 | $11.19 |
52-Week Low | $189.74 | $6.22 |
Enterprise Value | $17.08B | $890.95M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
